scholarly journals Response to Comment on: Bergenstal et al. A Randomized, Controlled Study of Once-Daily LY2605541, a Novel Long-Acting Basal Insulin, Versus Insulin Glargine in Basal Insulin-Treated Patients With Type 2 Diabetes. Diabetes Care 2012;35:2140-2147

Diabetes Care ◽  
2013 ◽  
Vol 36 (7) ◽  
pp. e107-e108
Author(s):  
R. M. Bergenstal ◽  
J. Rosenstock ◽  
R. F. Arakaki ◽  
M. J. Prince ◽  
Y. Qu ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Insulin Glargine ◽  
Diabetes Care ◽  
Basal Insulin ◽  
Randomized Controlled Study ◽  
Controlled Study ◽  
Once Daily ◽  
Randomized Controlled ◽  
Long Acting

Insulin Glargine: A New Basal Insulin

2002 ◽  
Vol 36 (6) ◽  
pp. 1019-1027 ◽  
Author(s):  
Terri L Levien ◽  
Danial E Baker ◽  
John R White ◽  
R Keith Campbell
Keyword(s):  
Type 2 Diabetes ◽  
Insulin Glargine ◽  
Basal Insulin ◽  
Nph Insulin ◽  
Once Daily ◽  
Nocturnal Hypoglycemia ◽  
Acting Insulin ◽  
Long Acting

OBJECTIVE: To review the pharmacology, pharmacokinetics, dosing guidelines, adverse effects, drug interactions, and clinical efficacy of insulin glargine. DATA SOURCES: Primary and review articles regarding insulin glargine were identified by MEDLINE search (1966–July 2001); abstracts were identified through Institute for Scientific Information Web of Science (1995–July 2001) and the American Diabetes Association. Additional information was obtained from the insulin glargine product information. STUDY SELECTION AND DATA EXTRACTION: All of the articles and meeting abstracts identified from the data sources were evaluated, and all information deemed relevant was included in this review. Priority was placed on data from the primary medical literature. DATA SYNTHESIS: Insulin glargine is a long-acting, recombinant human insulin analog that is given once daily as a basal source of insulin in patients with type 1 or type 2 diabetes mellitus. Modification of the basic insulin structure has produced a new insulin that is soluble at an acidic pH, but precipitates in the subcutaneous tissue and is slowly released from a depot. Insulin glargine has a slower onset of action than NPH insulin and a longer duration of action with no peak activity. Once-daily administration of insulin glargine has comparable efficacy to that of NPH insulin administered once or twice daily in basal-bolus regimens when used in combination with intermittent doses of regular insulin or insulin lispro in patients with type 1 and type 2 diabetes, and in conjunction with oral antidiabetic agents in patients with type 2 diabetes. Overall, insulin glargine has an incidence of hypoglycemia comparable to or less than that of NPH insulin, with a reduced incidence of nocturnal hypoglycemia compared with NPH insulin seen in some studies. CONCLUSIONS: Insulin glargine is a long-acting insulin analog capable of providing 24-hour basal insulin coverage when administered once daily at bedtime. Its activity profile, which lacks a pronounced peak, more closely resembles that of endogenous basal insulin than that of other intermediate- or long-acting insulins and appears more likely to be associated with a reduced incidence of hypoglycemia, particularly nocturnal hypoglycemia. Insulin glargine physiologically provides basal insulin but, for most patients, the addition of a rapid-acting insulin, like insulin lispro, before or with meals will need to be included in the treatment regimen to achieve optimal management of blood glucose concentrations.

Efficacy and Safety of Insulin Degludec and Insulin Glargine U-100 in Hospitalized Patients with Type 2 Diabetes—An Open-Label, Randomized Controlled Study

Diabetes ◽  
2018 ◽  
Vol 67 (Supplement 1) ◽  
pp. 302-OR
Author(s):  
JUN SUZUKI ◽  
TADASHI YAMAKAWA ◽  
MINORI SHINODA ◽  
RIKA SAKAMOTO ◽  
KENICHIRO TAKAHASHI ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Insulin Glargine ◽  
Insulin Degludec ◽  
Hospitalized Patients ◽  
Randomized Controlled Study ◽  
Controlled Study ◽  
Efficacy And Safety ◽  
Open Label ◽  
Randomized Controlled
Sign in / Sign up

Export Citation Format

Share Document